NCT00625014View on ClinicalTrials.gov

Metabolic Effects of Subchronic Dopamine D2 Receptor Blockade by Haloperidol in Healthy Humans

NACompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

March 31, 2005

Primary Completion Date

July 31, 2005

Study Completion Date

July 31, 2005

Conditions
Insulin ResistanceDyslipidemia
Interventions
DRUG

Haloperidol

Haloperidol 3 mg/day for 8 days

Trial Locations (1)

2300 RC

Leiden University Medical Center, Leiden

Sponsors
All Listed Sponsors
collaborator

Dutch Diabetes Research Foundation

OTHER

lead

Leiden University Medical Center

OTHER